Cardiol Therapeutics Inc.

TSX:CRDL Rapporto sulle azioni

Cap. di mercato: CA$211.5m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cardiol Therapeutics Gestione

Gestione criteri di controllo 2/4

Cardiol Therapeutics' Il CEO è David Elsley, nominato in Jan2017, e ha un mandato di 7.58 anni. la retribuzione annua totale è CA$ 748.10K, composta da 70.2% di stipendio e 29.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.72% delle azioni della società, per un valore di CA$ 3.34M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 2.6 anni.

Informazioni chiave

David Elsley

Amministratore delegato

CA$748.1k

Compenso totale

Percentuale dello stipendio del CEO70.2%
Mandato del CEO7.8yrs
Proprietà del CEO1.5%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Elsley rispetto agli utili di Cardiol Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-CA$29m

Mar 31 2024n/an/a

-CA$30m

Dec 31 2023CA$748kCA$525k

-CA$28m

Sep 30 2023n/an/a

-CA$28m

Jun 30 2023n/an/a

-CA$30m

Mar 31 2023n/an/a

-CA$29m

Dec 31 2022CA$654kCA$525k

-CA$31m

Sep 30 2022n/an/a

-CA$30m

Jun 30 2022n/an/a

-CA$32m

Mar 31 2022n/an/a

-CA$32m

Dec 31 2021CA$1mCA$455k

-CA$32m

Sep 30 2021n/an/a

-CA$35m

Jun 30 2021n/an/a

-CA$30m

Mar 31 2021n/an/a

-CA$27m

Dec 31 2020CA$517kCA$450k

-CA$21m

Sep 30 2020n/an/a

-CA$14m

Jun 30 2020n/an/a

-CA$13m

Mar 31 2020n/an/a

-CA$13m

Dec 31 2019CA$450kCA$450k

-CA$14m

Sep 30 2019n/an/a

-CA$20m

Jun 30 2019n/an/a

-CA$21m

Mar 31 2019n/an/a

-CA$19m

Dec 31 2018CA$713kCA$363k

-CA$16m

Compensazione vs Mercato: La retribuzione totale di David ($USD 541.91K ) è circa la media per le aziende di dimensioni simili nel mercato Canadian ($USD 725.52K ).

Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

David Elsley

7.8yrs

Mandato

CA$748,100

Compensazione

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Elsley
President7.8yrsCA$748.10k1.53%
CA$ 3.2m
Christopher Waddick
CFO, Corporate Secretary & Director6.2yrsCA$294.80k0.14%
CA$ 295.9k
Bernard Lim
Chief Operating Officer3.8yrsCA$515.90k0.038%
CA$ 80.7k
Andrew Hamer
Chief Medical Officer & Head of Research & Development3.6yrsCA$746.56k0.40%
CA$ 845.7k
Trevor Burns
Investor Relationsno dataNessun datoNessun dato
John Geddes
Vice President of Corporate Developmentless than a yearNessun datoNessun dato

3.8yrs

Durata media

Gestione esperta: Il team dirigenziale di CRDL è considerato esperto (durata media dell'incarico 4.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Elsley
President7.8yrsCA$748.10k1.53%
CA$ 3.2m
Christopher Waddick
CFO, Corporate Secretary & Director2.4yrsCA$294.80k0.14%
CA$ 295.9k
Colin Stott
Independent Director4.8yrsCA$60.00k0.18%
CA$ 383.3k
Jennifer Chao
Independent Director2.6yrsCA$76.92k0.13%
CA$ 269.0k
Peter Pekos
Independent Director6.8yrsCA$58.00k0.59%
CA$ 1.3m
Michael Willner
Independent Director3.1yrsCA$71.52k1.08%
CA$ 2.3m
Paul Ridker
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato
Bruce McManus
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato
Teri Loxam
Independent Director2.4yrsCA$82.32k0.15%
CA$ 322.8k
Guillermo Torre-Amione
Independent Chairman6.2yrsCA$112.68k0.28%
CA$ 593.2k
Joseph Hill
Member of Scientific Advisory Board2.8yrsNessun datoNessun dato

2.8yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CRDL non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.